Copaxone Now Deemed Safe for Pregnancy and Breastfeeding in Updated Guidelines

Teva Pharmaceuticals has updated the prescribing information for Copaxone (glatiramer acetate), offering clearer guidance on its use during pregnancy. The changes follow years of data collection and analysis, confirming no increased risks to pregnancy or neonatal health when the medication is used as directed.

The updated guidelines now allow women with high disease activity to continue Copaxone treatment after a risk-benefit assessment. This decision is supported by extensive pharmacovigilance data, including 618 documented pregnancies where mothers used Copaxone throughout all three trimesters between 1997 and 2020. These cases were recorded in Teva's global database, with additional findings from the German MS and Family Planning Register (DMSKW), which analysed 151 exposed pregnancies.

A broader review of 2,455 reported pregnancies with known outcomes found no safety concerns related to pregnancy progression or neonatal health. Earlier, in 2016, the German MS and Pregnancy Registry also reported no differences in birth defects, preterm births, or caesarean deliveries when Copaxone was used in the first trimester. The updated information now includes over 1,000 pregnancy outcomes, reinforcing that the drug does not raise the risk of fetal or neonatal toxicity.

The new guidance also introduces the concept of 'bridging'—continuing Copaxone until conception to avoid treatment gaps. Additionally, the drug can be safely used while breastfeeding, ensuring uninterrupted therapy for mothers who need it.

The revised prescribing information provides clearer options for women managing multiple sclerosis during pregnancy and breastfeeding. With no evidence of increased risks from Copaxone use, clinicians can now make more informed decisions about continuing treatment when necessary. The update reflects decades of real-world data, offering reassurance to patients and healthcare providers alike.